CorMedix (CRMD)
(Delayed Data from NSDQ)
$6.24 USD
+0.17 (2.80%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.23 -0.01 (-0.16%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
CorMedix Inc [CRMD]
Reports for Purchase
Showing records 1 - 20 ( 101 total )
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Update Conference Call Clarifies Regulatory Situation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
DefenCath Complete Response Letter Not a Showstopper; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Defencath Advisory Committee Meeting Ruled Unnecessary; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
3Q20 Financial Results; AdCom in January 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Defencath New Drug Application Accepted by FDA for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Defencath Approval Next Catalyst; 2Q20 Financials; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Defencath New Drug Application Submission Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
1Q20 Financials; Defencath Filing Completion Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2019 Financial Results; Neutrolin Filing Completion Nears; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
New Drug Application Rolling Review Authorized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Regulatory Filing on Track; 3Q19 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Initial Neutrolin Regulatory Filing Preparations Complete; FDA Meeting Scheduled; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; FDA Pathway Taking Shape; Securities Exchange Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
Taurolidine Preclinical Data Showcase Activity Against Neuroblastoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CorMedix Inc
Industry: Medical - Biomedical and Genetics
1Q19 Financials Reported; Neutrolin Filing Near Term; Reiterate Buy; Modulating Target to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R